It has been over a decade since the introduction of ralte-gravir, which has a well-established efﬁcacy and tolera-bility proﬁle . However, until recently, raltegravir hasonly been available as twice-daily formulations with, as aresult, a lower cumulative compliance to therapy and ahigher rate of discontinuation compared with the otheragents in the class .Following encouraging results from the ONCEMRK trial, a new raltegravir formulation of 1200 mg once dailywas introduced, and has been available in our centre sinceMay 2018. The new once-daily administration appearspromising in improving the compliance to raltegravir-con-taining regimens. However, during our routine clinicalactivity, we noticed that some of the patients recentlyswitched to raltegravir 1200 mg once daily were incor-rectly taking the drug. We then decided to investigate thisissue and to determine how widespread it was and pro-ceeded to recall all patients switched to this therapy in ourclinical centre between May 2018 and December 2018. Wethen asked our patients how they were taking raltegravirand collected their opinions on the ease of administrationof the new formulation and the onset of side effects.